IT and IV Lentiviral Gene Therapy for X-ALD

Recruiting now · Not applicable

Conditions studied: X-linked Adrenoleukodystrophy

In brief

This is a Phase I/II clinical trial of gene therapy for treating X-linked adrenoleukodystrophy using a high-safety, high-efficiency, self-inactivating lentiviral vector (LV) TYF-ABCD1 to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the intrathecal and intravenous lentiviral gene transfer clinical protocol.

Key facts

Study ID

NCT03727555

Run by

Shenzhen Geno-Immune Medical Institute

People needed

30

Starts

2025-08-31

Expected to finish

2028-12-31

Last updated by the study team

2025-09-09

Who can join

Age: 1 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• X-ALD patients ≥ 1 year of age
• ALD diagnosis of the brain: evaluation of the VLCFA value in plasma
• Central imaging of the MRI to examine the damage on the CNS.
• Neurological function score (NFS) ≥ 1
• Parent / guardian / patient signing informed consent
• Patients and their families have a strong willingness to participate in clinical trials, and are willing to bear all the consequences caused by the failure of the trial, and sign an informed consent form

You may not qualify if…

• HIV positive patients
• Stablized condition after statins, Lorenzo's oil, or diet to reduce VLCFA levels
• Patients who are experiencing severe viral, bacterial or fungal infections, malignant tumors, heart abnormalities, liver dysfunction, or renal insufficiency
• Cannot perform an MRI
• Infection or dermatosis at pre-injection site

Where it is running

• Shenzhen Geno-immune Medical Institute — Shenzhen, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.